Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | CCR1 | P32246 | 3/20 | 0.48 |
| ▸ | CCR5 | P51681 | 3/20 | 0.48 |
| ▸ | CCR8 | P51685 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16900278 | 0.79 | KDM4E (0.53) | KDM4ERAB9ANPC1MAPTGLA | |
| SCHEMBL752932 | 0.78 | RAB9A (0.52) | KDM4ERAB9ANPC1MAPTGLA | |
| SCHEMBL27605065 | 0.75 | KDM4E (0.49) | KDM4ERAB9ANPC1MAPTGLA | |
| SCHEMBL6851830 | 0.75 | KDM4E (0.48) | KDM4ERAB9ANPC1MAPTGLA | |
| SCHEMBL29871158 | 0.75 | GRM5 (0.51) | KDM4ERAB9ANPC1MAPTGLA | |
| SCHEMBL28543412 | 0.75 | NPC1 (0.48) | KDM4ERAB9ANPC1MAPTGLA | |
| SCHEMBL30956783 | 0.73 | HDAC1 (0.40) | KDM4ERAB9ANPC1CYP1A2HDAC1 | |
| SCHEMBL753210 | 0.72 | KDM4E (0.72) | KDM4ERAB9ANPC1MAPTGLA | |
| SCHEMBL3069800 | 0.72 | KDM4E (1.00) | KDM4ERAB9ANPC1MAPTGLA | |
| SCHEMBL25183185 | 0.72 | KDM4E (0.35) | KDM4ERAB9ANPC1MAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250281465-A1 | MOLECULES THAT ENHANCE EXTRACELLULAR VESICLE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-11 | — | — | US | disclosed |
| WO-2023212095-A1 | MOLECULES THAT ENHANCE EXTRACELLULAR VESICLE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-02 | — | — | WO | disclosed |
| US-7514567-B2 | Oxazolidinone nicotinic acetylcholine receptor agonists | ASTRAZENECA AB (SE) | 2009-04-07 | — | — | US | disclosed |
| US-7514567-B2 | Oxazolidinone nicotinic acetylcholine receptor agonists | ASTRAZENECA AB (SE) | 2009-04-07 | — | — | US | disclosed |
| US-7514567-B2 | Oxazolidinone nicotinic acetylcholine receptor agonists | ASTRAZENECA AB (SE) | 2009-04-07 | — | — | US | disclosed |
| CN-1829721-A | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | disclosed |
| US-20060154945-A1 | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | US | disclosed |
| EP-1654264-A1 | SPIRO [1-AZABICYCLO [2.2.2]OCTANE-3,5'-OXAZOLIDIN-2'-ONE] DERIVATIVES WITH AFFINITY TO THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005005435-A1 | SPIRO ′1-AZABICYCLO ′2.2.2!OCTAN-3,5′-OXAZOLIDIN -2′-ONE! DERIVATIVES WITH AFFINITY TO THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281465-A1 | MOLECULES THAT ENHANCE EXTRACELLULAR VESICLE RELEASE | ORAI1, CHERP, CASR | KDM4E 3336/4885RAB9A 512/4885NPC1 2093/4885 |
| US-20060154945-A1 | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | CHRNA1, CHRNA7, ADRA1D | KDM4E 4326/4885RAB9A 2444/4885NPC1 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.